Inside PIC/S: Implementing Quality Risk Management - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside PIC/S: Implementing Quality Risk Management
Representatives to the PIC/S provide an example of methodology for implementing ICH Q9.


Pharmaceutical Technology
Volume 33, Issue 12

The International Conference on Harmonization guideline on quality risk management, ICH Q9, addresses active substances and medicinal products, and was adopted by the European Union and Pharmaceutical Inspection Cooperation Scheme (PIC/S) in Annex 20 of their good manufacturing practice (GMP) guides. Drug manufacturers are gradually implementing quality risk-management principles as introduced in sections 1.5 and 1.6 of the European Union's GMP Guide, Part I. However, the practical methods for these new requirements are still perceived as difficult to interpret and apply.

In this context, a small, informal PIC/S working group is developing an objective and pragmatic example of methodology for ICH Q9 that can be used by the widest audience. The methodology will meet the demands of operators and inspectors and comply with all regulatory requirements. The main axes of this methodology are presented in this article; a complete description with examples of how the methodology can be implemented is available on the PIC/S website ( http://www.picscheme.org/).

The methodology example is meant to be used for training and will not be issued as a PIC/S recommendation or guideline. The example will not influence the outcome of PIC/S inspections.

Primary methodological axes

The proposed methodology comprises an exhaustive review of the various stages that have an effect on the intrinsic quality of the product. These steps include:

  • The inventory and evaluation of primary risks
  • The application of measures for the reduction of these risks
  • The evaluation of residual risks.

For each recorded stage, risk is traditionally assessed according to potential severity and frequency of the risk occuring. The manufacturer's ability to detect risk and the experience gained in performing the step in question also help determine the risk involved.

Integrating a quantified experience factor in risk calculation with an objective scale serves as a major achievement in the field of risk management. Calculated in this manner, the level of evaluated risk expresses the degree of technical mastery acquired in the performance of each process step for the concerned perimeter, without having to take into account the specific characteristics of the products involved. This is the first phase of the methodology and has been named System Risk.

The second phase of the risk-management methodology considers the integration of the particular properties of the products themselves whose System Risk will have been previously assessed. This integration is done using a modulating factor, the P-factor, which, multiplied with the System Risk gives the Total Risk.

The P-factor takes into consideration the intrinsic physicochemical and pharmaco-toxological characteristics of the product as well as parameters expressing knowledge levels and experience gained by the manufacturer for the product concerned.

This dual approach makes it possible to significantly reduce the burden (i.e., resources) of risk management. For example, the methodology avoids the needless repetitions of risk-evaluation steps that are typically conducted during the introduction of a new product.

By implementing a risk-management policy that integrates the steps defined above, a manufacturer in the pharmaceutical area can maintain the relevance of its risk levels and evaluate them for a total risk calculation. A risk-management policy should also envisage provisions for the identification and inclusion of developments that could potentially modify the result of an initial risk evaluation. Such developments may be internal or external to the company and may or may not be integrated into the manufacturer's quality system.

Traditionally, these developments include the management of corrective actions and preventive actions, deviations, change control, and internal and external information (e.g., GMP modification). Finally, a company's methodology of risk management should be organized according to an iterative process.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here